Hologic price target raised to $82 from $81 at RBC Capital

RBC Capital raised the firm’s price target on Hologic to $82 from $81 and keeps a Sector Perform rating on the shares. The company posted solid Q3 results on top and bottom line, though it also slightly lowered the midpoint of FY24 revenue guide on a stop-ship order for a non-core product, the analyst tells investors in a research note.